Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 3Phase 3 2Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Carcinoma, Renal Cell 3Neoplasm Metastasis 2Kidney Neoplasms 2Urogenital Neoplasms 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1PRETEXT I Hepatoblastoma 1Lymphoma, Mantle-Cell 1Lymphoma 1Breast Neoplasms 1

Interventions

Leucovorin 22Fluorouracil 22Gemcitabine 21Capecitabine 21Paclitaxel 20Docetaxel 20Irinotecan 15Carboplatin 15Radiosurgery 14Oxaliplatin 13Cisplatin 13Bevacizumab 13Zoledronic Acid 12pembrolizumab 11Radiotherapy 11Fulvestrant 11palbociclib 9Pemetrexed 9Drug Therapy 9130-nm albumin-bound paclitaxel 9Surgical Procedures, Operative 7Letrozole 7Ibandronic Acid 7abemaciclib 6Trastuzumab 6Prednisone 6Vinorelbine 5Folfox protocol 5Floxuridine 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasm Metastasis × temsirolimus × Clear all
NCT00474786 2013-11-21

INTORSECT

Pfizer

Phase 3 Completed
512 enrolled 16 charts
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT00083993 2011-11-08

Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Terminated
1,236 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡